Brian G Gazzard

Summary

Affiliation: Chelsea and Westminster Hospital
Country: UK

Publications

  1. ncbi request reprint Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients
    Brian G Gazzard
    Chelsea and Westminster Hospital, London SW10 9NH, UK
    Expert Opin Pharmacother 7:793-802. 2006
  2. ncbi request reprint British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005)
    B Gazzard
    Chelsea and Westimnster Hospital, London, UK
    HIV Med 6:1-61. 2005
  3. ncbi request reprint British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006)
    B Gazzard
    Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK
    HIV Med 7:487-503. 2006
  4. ncbi request reprint Antiretroviral therapy for HIV: medical miracles do happen
    Brian Gazzard
    Department of HIV, Chelsea and Westminster Hospital, London SW10 9NH, UK
    Lancet 366:346-7. 2005
  5. ncbi request reprint Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    AIDS 18:1291-7. 2004
  6. ncbi request reprint HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation
    Alan Steel
    Department of Immunology, Imperial College, Chelsea and Westminster Hospital, London
    Antivir Ther 12:971-5. 2007
  7. ncbi request reprint The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine
    Michael Sproat
    St Stephens Centre, Chelsea and Westminster Healthcare NHS Trust, London, UK
    Antivir Ther 10:357-61. 2005
  8. ncbi request reprint Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome
    John C Walsh
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    AIDS 16:269-77. 2002
  9. ncbi request reprint The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml
    Philippa J Easterbrook
    Department of HIV GUM, Guy s, King s and St Thomas School of Medicine, King s College Hospital, London, UK
    AIDS 16:1521-7. 2002
  10. ncbi request reprint An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance
    Brian G Gazzard
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    AIDS 17:F49-54. 2003

Detail Information

Publications52

  1. ncbi request reprint Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients
    Brian G Gazzard
    Chelsea and Westminster Hospital, London SW10 9NH, UK
    Expert Opin Pharmacother 7:793-802. 2006
    ..In these trials, long-term durability data are available for < or = 96 weeks...
  2. ncbi request reprint British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005)
    B Gazzard
    Chelsea and Westimnster Hospital, London, UK
    HIV Med 6:1-61. 2005
  3. ncbi request reprint British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006)
    B Gazzard
    Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK
    HIV Med 7:487-503. 2006
  4. ncbi request reprint Antiretroviral therapy for HIV: medical miracles do happen
    Brian Gazzard
    Department of HIV, Chelsea and Westminster Hospital, London SW10 9NH, UK
    Lancet 366:346-7. 2005
  5. ncbi request reprint Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    AIDS 18:1291-7. 2004
    ..To determine the pharmacokinetics of saquinavir hard-gel capsules/ritonavir/atazanavir co-administered once daily at 1600/100/300 mg in HIV-infected individuals...
  6. ncbi request reprint HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation
    Alan Steel
    Department of Immunology, Imperial College, Chelsea and Westminster Hospital, London
    Antivir Ther 12:971-5. 2007
    ..To determine if the expression of CD38 on CD8+ T-cells could be used as a marker of viral replication <50 copies/ml in peripheral blood...
  7. ncbi request reprint The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine
    Michael Sproat
    St Stephens Centre, Chelsea and Westminster Healthcare NHS Trust, London, UK
    Antivir Ther 10:357-61. 2005
    ..The relevance of this to clinical outcomes remains unclear. In this study, we compared the virological response of ddl- and non-ddl-containing regimens in the presence or absence of the M184V mutation...
  8. ncbi request reprint Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome
    John C Walsh
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    AIDS 16:269-77. 2002
    ..The Medication Adherence Self-Report Inventory (MASRI) has been developed and tested for its validity against objective measures and treatment outcome...
  9. ncbi request reprint The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml
    Philippa J Easterbrook
    Department of HIV GUM, Guy s, King s and St Thomas School of Medicine, King s College Hospital, London, UK
    AIDS 16:1521-7. 2002
    ..To determine the prevalence and prognostic significance of intermittent viraemia (IV) in patients who attained an undetectable viral load (VL) < 400 copies/ml within 6 months on highly active antiretroviral therapy (HAART)...
  10. ncbi request reprint An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance
    Brian G Gazzard
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    AIDS 17:F49-54. 2003
    ..TMC 125 was studied in HIV-1 infected patients with high-level phenotypic NNRTI resistance in an open-label phase IIa trial...
  11. ncbi request reprint Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma
    Tom Powles
    Department of Oncology, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    AIDS 16:531-6. 2002
    ....
  12. ncbi request reprint Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection
    Graeme J Moyle
    Chelsea and Westminster Hospital, London, United Kingdom
    J Infect Dis 191:866-72. 2005
    ..The determination of coreceptor tropism may be required before CCR5 or CXCR4 antagonists are initiated, unless reliable predictive markers of coreceptor use are established...
  13. pmc Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV cohort, 1988-2010
    Sundhiya Mandalia
    Department of Medicine, Imperial College London, Chelsea and Westminster Hospital, London, United Kingdom
    PLoS ONE 7:e29844. 2012
    ..Few LTNP and HIC identified in this and other studies, endorse the need for universal definitions to facilitate comparison...
  14. ncbi request reprint Interleukin-2-associated viral breakthroughs induce HIV-1-specific CD4 T cell responses in patients on fully suppressive highly active antiretroviral therapy
    Ann K Sullivan
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    AIDS 17:628-9. 2003
    ..This immunotherapeutic approach, utilizing autologous virus as autovaccination, may be a viable, safer alternative to structured treatment interruption and potentially more efficacious than therapeutic vaccines...
  15. ncbi request reprint Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin
    Yvonne C Gilleece
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    J Acquir Immune Defic Syndr 40:41-6. 2005
    ..To evaluate treatment outcome of acute hepatitis C virus (HCV) in HIV-positive individuals...
  16. doi request reprint Reduced T(H)1/T(H)17 CD4 T-cell numbers are associated with impaired purified protein derivative-specific cytokine responses in patients with HIV-1 infection
    Sally Clark
    Immunology Section, Division of Infectious Diseases, Imperial College, Chelsea and Westminster Hospital Campus, London, UK
    J Allergy Clin Immunol 128:838-846.e5. 2011
    ..Selective loss of T(H)1/T(H)17 cells in patients with HIV-1 infection might contribute to reduced tuberculosis-induced immune responses and an increased susceptibility to active tuberculosis...
  17. doi request reprint Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK
    P J Easterbrook
    Department of HIV GU Medicine, Kings College London School of Medicine at Guy s, London, UK
    HIV Med 9:47-56. 2008
    ..We describe the patterns of antiretroviral drug use at treatment initiation from 1996 to 2005 in a large UK multicentre cohort...
  18. ncbi request reprint Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis
    Christos Michailidis
    Chelsea and Westminster Hospital NHS Trust, London, UK
    Antivir Ther 10:417-22. 2005
    ..The aetiology of these immune reconstitution inflammatory syndrome (IRIS) reactions is unknown but it is presumed that they occur, at least in part, as a consequence of HAART-related reconstitution of immunity...
  19. ncbi request reprint Does atazanavir cause lipodystrophy?
    Brian G Gazzard
    The Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    J HIV Ther 9:41-4. 2004
    ..This feature has been widely interpreted as implying that in the future there will be no abnormalities associated with fat redistribution when the drug is administered. This article explores that view...
  20. ncbi request reprint Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study
    Gail V Matthews
    Department of HIV Medicine, Chelsea Hospital, London, UK
    AIDS 16:53-61. 2002
    ....
  21. ncbi request reprint Elevated mucosal addressin cell adhesion molecule-1 expression in acquired immunodeficiency syndrome is maintained during antiretroviral therapy by intestinal pathogens and coincides with increased duodenal CD4 T cell densities
    Yin M Miao
    HIV GUM Directorate, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, United Kingdom
    J Infect Dis 185:1043-50. 2002
    ..After HAART, opportunistic intestinal pathogens maintain elevated MAdCAM-1 expression, which results in prominent increases in LP CD4 T cell densities in the absence of HIV-mediated CD4 T cell destruction...
  22. ncbi request reprint British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy
    A Pozniak
    Chelsea and Westminster Hospital, London, UK
    HIV Med 4:1-41. 2003
  23. doi request reprint Short communication: NKG2C+ NK cells contribute to increases in CD16+CD56- cells in HIV type 1+ individuals with high plasma viral load
    John N S Gregson
    Department of Immunology, Imperial College London, Chelsea and Westminster Hospital, London, United Kingdom
    AIDS Res Hum Retroviruses 29:84-8. 2013
    ..These data, in addition to anti-HCMV IgG serology, indicate a potential contribution of both HCMV and HIV-1 to NK cell dysfunction in HIV-1-infected individuals...
  24. ncbi request reprint A case of march fracture in a patient with osteoporosis on long-term HAART
    Sophie F Forsyth
    Kobler Centre, St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    Int J STD AIDS 13:645-6. 2002
  25. ncbi request reprint Opportunistic protozoan diarrhoea
    Yin M Miao
    Department of HIV Medicine, St Stephen s Centre, Chelsea and Westminister Hospital, London, UK
    J HIV Ther 7:17-20. 2002
    ..In this review, we examine current management practices for HIV-related opportunistic protozoan diarrhoea..
  26. ncbi request reprint Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors
    Graeme J Moyle
    Chelsea and Westminster Hospital, London, UK
    AIDS 16:1341-9. 2002
    ..To evaluate the prevalence, outcome and possible risk factors for hyperlactataemia and lactic acidosis in HIV-positive persons receiving antiretroviral therapy...
  27. doi request reprint Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients
    Amanda Mocroft
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, Division of Population Health, University College London Medical School, Royal Free Campus, London, UK
    AIDS 24:1667-78. 2010
    ..Chronic kidney disease (CKD) in HIV-positive persons might be caused by both HIV and traditional or non-HIV-related factors. Our objective was to investigate long-term exposure to specific antiretroviral drugs and CKD...
  28. doi request reprint Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study
    R J C Gilson
    Centre for Sexual Health and HIV Research, Research Department of Infection and Population Health, University College London, The Mortimer Market Centre, Camden Primary Care Trust, London, UK
    HIV Med 11:152-60. 2010
    ..This study was designed to determine the incidence of a discordant response at two time-points, soon after 6 months and at 12 months, and to determine the relationship with clinical outcomes...
  29. pmc Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study
    Rebecca K Lodwick
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, UCL Medical School, Royal Free Campus, London, UK
    Lancet 376:340-5. 2010
    ..We aimed to examine this by analysis of pooled data from industrialised countries...
  30. pmc CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK
    Mark Bower
    Research Department of Infection and Population Health, Division of Population Health, UCL Medical School, Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK
    Haematologica 94:875-80. 2009
    ..Earlier highly active anti-retroviral therapy initiation and wider access to HIV testing is advocated to reduce the risk of systemic non-Hodgkin's lymphoma...
  31. pmc Interruption of antiretroviral therapy is associated with increased plasma cystatin C
    Amanda Mocroft
    University College London Medical School, London, UK
    AIDS 23:71-82. 2009
    ....
  32. doi request reprint The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy
    C A Sabin
    Department of Primary Care and Population Science, Royal Free and UC Medical School, London, UK
    HIV Med 10:35-43. 2009
    ....
  33. doi request reprint The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes
    J Turner
    Centre for Sexual Health and HIV Research, UCL Medical School and The Mortimer Market Centre, Camden Primary Care Trust, London, UK
    J Viral Hepat 17:569-77. 2010
    ..HCV infection had no impact on HIV virological outcomes or immunological response to HIV treatment. The long-term impact on morbidity and mortality remain to be determined...
  34. pmc Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection
    Alison J Rodger
    HIV Epidemiology and Biostatistics Group, Research Dept of Infection and Population Health, UCL Medical School, University College London, London, UK
    J Infect Dis 200:973-83. 2009
    ..Their associations with opportunistic disease (OD) in human immunodeficiency virus (HIV)-positive patients were examined...
  35. doi request reprint Serious fatal and nonfatal non-AIDS-defining illnesses in Europe
    Amanda Mocroft
    Research Department of Infection and Population Health, University College Medical School, London, UK
    J Acquir Immune Defic Syndr 55:262-70. 2010
    ..Little is known about the incidence and risk factors for serious non-AIDS-defining events...
  36. doi request reprint Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy
    Richard T Davey
    National Institutes of Health, National Institute of Allergy and Infectious Disease, Bethesda, MD 20892, USA
    J Interferon Cytokine Res 28:89-100. 2008
    ..Bay 50-4798 was generally well tolerated across the dose range tested, but a lack of potent, sustained immunologic activity suggests that further optimization of dose and schedule will be necessary...
  37. ncbi request reprint Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis
    Graeme J Moyle
    AIDS 16:1086-7. 2002
  38. ncbi request reprint Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel
    Patrick G Yeni
    Department of Infectious Diseases, Hopital Bichat Claude Bernard, X Bichat Medical School, Paris, France
    JAMA 292:251-65. 2004
    ..Substantial changes in the field of human immunodeficiency virus (HIV) treatment have occurred in the last 2 years, prompting revision of the guidelines for antiretroviral management of adults with established HIV infection...
  39. ncbi request reprint Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors?
    John F Morlese
    AIDS 16:1840-1. 2002
  40. ncbi request reprint Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel
    Patrick G Yeni
    Hopital Bichat Claude Bernard, Department of Infectious Diseases, 46 rue Henri Huchard, Paris, Cedex 18 France 75877
    JAMA 288:222-35. 2002
    ..These updated recommendations are intended to guide practicing physicians actively involved in human immunodeficiency virus (HIV)- and acquired immunodeficiency syndrome (AIDS)-related care...
  41. ncbi request reprint True gynaecomastia, another manifestation of immune reconstitution disease?
    Nadeem A Qazi
    Int J STD AIDS 13:59-65. 2002
  42. ncbi request reprint The efficacy of lopinavir in individuals experiencing protease inhibitor failure
    Yvonne C Gilleece
    J Acquir Immune Defic Syndr 32:238-40. 2003
  43. ncbi request reprint Clinical utility of resistance testing
    Justin Stebbing
    J HIV Ther 7:75-9. 2002
  44. ncbi request reprint Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel
    Scott M Hammer
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    JAMA 296:827-43. 2006
    ..The International AIDS Society-USA panel has updated its recommendations as warranted by new developments in the field...
  45. ncbi request reprint Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens
    Simon P Jones
    Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom
    J Acquir Immune Defic Syndr 40:565-72. 2005
    ....
  46. pmc When should antiretroviral therapy for HIV be started?
    Andrew N Phillips
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London NW3 2PF
    BMJ 334:76-8. 2007
  47. ncbi request reprint Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: lack of reversion with highly active antiretroviral therapy
    Christopher M Mela
    Department of Immunology, Imperial College, UK
    AIDS 19:1761-9. 2005
    ..Exceptionally, for an inhibitory receptor, the proportion of NK cells bearing CD94-NKG2A decreases during HIV-1 infection. It is not understood whether HIV-1 itself or other concomitant infections drive these changes...
  48. ncbi request reprint Depletion of natural killer cells in the colonic lamina propria of viraemic HIV-1-infected individuals
    Christopher M Mela
    Department of Immunology, Imperial College London, UK
    AIDS 21:2177-82. 2007
    ..HIV-1 infection is known to have a detrimental impact on peripheral blood natural killer cell phenotype and function. Chronic HIV-1 also causes a substantial depletion of CD4+ T cells in the gastrointestinal tract and the blood...
  49. pmc Rising rates of HIV infection
    Angela J Robinson
    BMJ 330:320-1. 2005
  50. ncbi request reprint Gynaecomastia without lipodystrophy in HIV-1-seropositive patients on efavirenz: an alternative hypothesis
    Nadeem A Qazi
    AIDS 16:506-7. 2002
  51. ncbi request reprint Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection
    John F Morlese
    AIDS 17:1411-3. 2003
  52. ncbi request reprint The management of meningeal lymphoma in patients with HIV in the era of HAART: intrathecal depot cytarabine is effective and safe
    Danish Mazhar
    Blood 107:3412-4. 2006